AngioDynamics (NSDQ:ANGO) agreed to pay a total of nearly $13 million to settle charges that it broke the False Claims Act for a chemotherapy delivery device and a peripheral vein treatment.
Latham, N.Y.-based AngioDynamics distributed the LC Bead embolization microspheres made by BTG (LON:BTG) subsidiary Biocompatibles. Although cleared for embolizations, the companies allegedly marketed LC Bead from May 2006 through December 2011 as a drug-delivery vehicle for chemotherapy agents, according to federal prosecutors in New York and Texas. The company admitted no liability in agreeing to the settlements, they said.
